MARKSANS Q1 FY27 results at a glance
MARKSANS PHARMA LIMITED Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹841 cr |
|---|
| Revenue YoY | +35.6% |
|---|
| Operating profit | ₹188 cr |
|---|
| Operating margin | 22.4% |
|---|
| Net profit | ₹157 cr |
|---|
| Net profit YoY | +169.5% |
|---|
| Net profit QoQ | +6.1% |
|---|
| Net margin | 18.7% |
|---|
| Basic EPS | ₹3.47 |
|---|
| TTM revenue | ₹3,172 cr |
|---|
| TTM net profit | ₹517 cr |
|---|
| TTM net margin | 16.3% |
|---|
MARKSANS Q1 FY27 results: what the numbers say
MARKSANS PHARMA LIMITED (MARKSANS) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹841 cr and a net profit of ₹157 cr, translating into earnings per share of ₹3.47.
Compared with the same quarter a year earlier, revenue grew strongly by +35.6% and net profit grew sharply by +169.5%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹188 cr, an operating margin of 22.4% versus 12.4% a year ago — a gain of 10.0 percentage points.
MARKSANS quarter-wise results table
Net profit
₹157 cr
+169.5% YoY
Operating profit
₹188 cr
+144.3% YoY
MARKSANS PHARMA LIMITED (MARKSANS) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹841 cr | ₹188 cr | ₹157 cr | 22.4% | 18.7% | ₹3.47 | +169.5% | +6.1% |
| Q4 FY262026-03-31 | ₹856 cr | ₹171 cr | ₹148 cr | 20.0% | 17.3% | ₹3.27 | — | +30.9% |
| Q3 FY262025-12-31 | ₹754 cr | ₹136 cr | ₹113 cr | 18.1% | 15.0% | ₹2.50 | — | +15.2% |
| Q2 FY262025-09-30 | ₹720 cr | ₹118 cr | ₹98.25 cr | 16.3% | 13.6% | ₹2.17 | — | +68.5% |
| Q1 FY262025-06-30 | ₹620 cr | ₹77.02 cr | ₹58.32 cr | 12.4% | 9.4% | ₹1.29 | — | — |
| TTM (last 4 quarters) | ₹3,172 cr | ₹613 cr | ₹517 cr | 19.3% | 16.3% | ₹11.41 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
MARKSANS quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
MARKSANS PHARMA LIMITED quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹841 cr | ₹856 cr | ₹754 cr | ₹720 cr | ₹620 cr |
|---|
| Total expenses | ₹653 cr | ₹685 cr | ₹618 cr | ₹603 cr | ₹543 cr |
|---|
| Gross profit | ₹497 cr | ₹465 cr | ₹438 cr | ₹412 cr | ₹358 cr |
|---|
| Operating profit (EBIT) | ₹188 cr | ₹171 cr | ₹136 cr | ₹118 cr | ₹77.02 cr |
|---|
| Operating margin | 22.4% | 20.0% | 18.1% | 16.3% | 12.4% |
|---|
| Interest cost | ₹7 cr | ₹6.31 cr | ₹5.94 cr | ₹5.82 cr | ₹6.07 cr |
|---|
| Profit before tax | ₹207 cr | ₹200 cr | ₹151 cr | ₹133 cr | ₹76.6 cr |
|---|
| Tax expense | ₹47.16 cr | ₹50.97 cr | ₹36.93 cr | ₹34.2 cr | ₹18.4 cr |
|---|
| Effective tax rate | 22.8% | 25.5% | 24.5% | 25.6% | 24.0% |
|---|
| Net profit (PAT) | ₹157 cr | ₹148 cr | ₹113 cr | ₹98.25 cr | ₹58.32 cr |
|---|
| Net profit margin | 18.7% | 17.3% | 15.0% | 13.6% | 9.4% |
|---|
| Basic EPS | ₹3.47 | ₹3.27 | ₹2.50 | ₹2.17 | ₹1.29 |
|---|
| Diluted EPS | ₹3.47 | ₹3.27 | ₹2.50 | ₹2.17 | ₹1.29 |
|---|
MARKSANS results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +35.6% | — | — | — | — |
|---|
| Revenue QoQ | -1.8% | +13.5% | +4.7% | +16.2% | — |
|---|
| Operating profit YoY | +144.3% | — | — | — | — |
|---|
| Operating profit QoQ | +10.0% | +25.5% | +16.0% | +52.7% | — |
|---|
| Net profit YoY | +169.5% | — | — | — | — |
|---|
| Net profit QoQ | +6.1% | +30.9% | +15.2% | +68.5% | — |
|---|
| EPS YoY | +169.0% | — | — | — | — |
|---|
| EPS QoQ | +6.1% | +30.8% | +15.2% | +68.2% | — |
|---|
MARKSANS annual results history
Full-year performance for MARKSANS PHARMA LIMITED, useful for reading each quarter in context.
MARKSANS PHARMA LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹2,942 cr | ₹2,614 cr | ₹2,174 cr | ₹1,850 cr |
|---|
| Total expenses | ₹2,426 cr | ₹2,159 cr | ₹1,787 cr | ₹1,537 cr |
|---|
| Gross profit | ₹1,569 cr | ₹1,385 cr | ₹1,077 cr | ₹892 cr |
|---|
| Operating profit (EBIT) | ₹515 cr | ₹456 cr | ₹387 cr | ₹313 cr |
|---|
| Operating margin | 17.5% | 17.4% | 17.8% | 16.9% |
|---|
| Interest cost | ₹24.13 cr | ₹11.66 cr | ₹11.2 cr | ₹5.75 cr |
|---|
| Profit before tax | ₹561 cr | ₹504 cr | ₹424 cr | ₹338 cr |
|---|
| Tax expense | ₹140 cr | ₹121 cr | ₹109 cr | ₹72.33 cr |
|---|
| Effective tax rate | 25.1% | 24.1% | 25.6% | 21.4% |
|---|
| Net profit (PAT) | ₹418 cr | ₹381 cr | ₹314 cr | ₹266 cr |
|---|
| Net profit margin | 14.2% | 14.6% | 14.4% | 14.4% |
|---|
| Basic EPS | ₹9.22 | ₹8.40 | ₹6.92 | ₹6.41 |
|---|
| Diluted EPS | ₹9.22 | ₹8.40 | ₹6.92 | ₹6.41 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹841 cr against ₹620 cr in Q1 FY26, and ₹856 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -1.8%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹653 cr, or 77.6% of revenue, with operating profit grew +144.3% year on year.
Margins, tax and profitability
Net profit of ₹157 cr works out to a net margin of 18.7% compared with 9.4% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, MARKSANS PHARMA LIMITED reported profit before tax of ₹207 cr, a tax charge of ₹47.16 cr (effective rate 22.8%), interest cost of ₹7 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹148 cr in Q4 FY26 to ₹157 cr in Q1 FY27, a change of +6.1%.
Trailing twelve months and annual context
Across the trailing four quarters MARKSANS PHARMA LIMITED has generated revenue of ₹3,172 cr and net profit of ₹517 cr, a trailing net margin of 16.3%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹2,942 cr with net profit of ₹418 cr and EPS of ₹9.22, versus the prior year where revenue grew +12.5% and profit grew +9.8%.
What to watch in the next MARKSANS quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
MARKSANS PHARMA LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
MARKSANS results coverage
No results report published for MARKSANS yet — our desk covers each quarter within minutes of the filing.
MARKSANS quarterly results FAQs
What were MARKSANS PHARMA LIMITED (MARKSANS) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), MARKSANS PHARMA LIMITED reported revenue of ₹841 cr and net profit of ₹157 cr, a change of +169.5% year on year on +35.6% revenue growth. EPS stood at ₹3.47.
What is MARKSANS profit margin in Q1 FY27?
MARKSANS PHARMA LIMITED posted a net profit margin of 18.7% and an operating margin of 22.4% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹3,172 cr and net profit ₹517 cr.
Did MARKSANS results beat the previous quarter?
MARKSANS PHARMA LIMITED net profit changed +6.1% quarter on quarter, from ₹148 cr in Q4 FY26 to ₹157 cr in Q1 FY27.
When are MARKSANS PHARMA LIMITED (MARKSANS) quarterly results?
MARKSANS PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see MARKSANS latest quarterly results?
Results coverage for MARKSANS will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the MARKSANS stock page.
What is MARKSANS PHARMA LIMITED annual revenue and profit?
For FY26, MARKSANS PHARMA LIMITED reported full-year revenue of ₹2,942 cr and net profit of ₹418 cr, with EPS of ₹9.22.
How many quarterly results has MARKSANS declared recently?
Past results dates for MARKSANS will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
